201 related articles for article (PubMed ID: 37772924)
1. Alk-rearranged lung adenocarcinoma: From molecular genetics to therapeutic targeting.
Testa U; Castelli G; Pelosi E
Tumori; 2024 Apr; 110(2):88-95. PubMed ID: 37772924
[TBL] [Abstract][Full Text] [Related]
2. ALK inhibitors in the treatment of advanced NSCLC.
Gridelli C; Peters S; Sgambato A; Casaluce F; Adjei AA; Ciardiello F
Cancer Treat Rev; 2014 Mar; 40(2):300-6. PubMed ID: 23931927
[TBL] [Abstract][Full Text] [Related]
3. ALK-positive lung cancer: a moving target.
Schneider JL; Lin JJ; Shaw AT
Nat Cancer; 2023 Mar; 4(3):330-343. PubMed ID: 36797503
[TBL] [Abstract][Full Text] [Related]
4. Drug resistance in anaplastic lymphoma kinase-rearranged lung cancer.
Katayama R
Cancer Sci; 2018 Mar; 109(3):572-580. PubMed ID: 29336091
[TBL] [Abstract][Full Text] [Related]
5. Targeting SLMAP-ALK-a novel gene fusion in lung adenocarcinoma.
Pagan C; Barua S; Hsiao SJ; Mansukhani M; Saqi A; Murty V; Fernandes H
Cold Spring Harb Mol Case Stud; 2019 Jun; 5(3):. PubMed ID: 31160357
[TBL] [Abstract][Full Text] [Related]
6. Anaplastic lymphoma kinase inhibitors in phase I and phase II clinical trials for non-small cell lung cancer.
Karachaliou N; Santarpia M; Gonzalez Cao M; Teixido C; Sosa AE; Berenguer J; Rodriguez Capote A; Altavilla G; Rosell R
Expert Opin Investig Drugs; 2017 Jun; 26(6):713-722. PubMed ID: 28463570
[TBL] [Abstract][Full Text] [Related]
7. Transformation of invasive lung adenocarcinoma with ALK rearrangement into pulmonary sarcomatoid carcinoma.
Xie X; Chen X; Luo N; Qi Y; Li M; Feng X
J Cancer Res Clin Oncol; 2022 Aug; 148(8):2165-2168. PubMed ID: 35426613
[TBL] [Abstract][Full Text] [Related]
8. Rapid and durable response to fifth-line lorlatinib plus olaparib in an ALK -rearranged, BRCA2-mutated metastatic lung adenocarcinoma patient with critical tracheal stenosis: a case report.
Jin C; He Z; Guo M; Liu S; Wang Y; Qiu J; Li C; Wu D
Anticancer Drugs; 2022 Aug; 33(7):696-700. PubMed ID: 35324529
[TBL] [Abstract][Full Text] [Related]
9. Resistance to Crizotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) with ALK Rearrangement: Mechanisms, Treatment Strategies and New Targeted Therapies.
Casaluce F; Sgambato A; Sacco PC; Palazzolo G; Maione P; Rossi A; Ciardiello F; Gridelli C
Curr Clin Pharmacol; 2016; 11(2):77-87. PubMed ID: 27138017
[TBL] [Abstract][Full Text] [Related]
10. De novo ALK kinase domain mutations are uncommon in kinase inhibitor-naïve ALK rearranged lung cancers.
Lucena-Araujo AR; Moran JP; VanderLaan PA; Dias-Santagata D; Folch E; Majid A; Kent MS; Gangadharan SP; Rangachari D; Huberman MS; Kobayashi SS; Costa DB
Lung Cancer; 2016 Sep; 99():17-22. PubMed ID: 27565908
[TBL] [Abstract][Full Text] [Related]
11. Anaplastic Lymphoma Kinase Fusion: A Review of Therapeutic Drugs and Treatment Strategies.
Makimoto G; Ohashi K; Maeda Y; Kiura K
Acta Med Okayama; 2020 Oct; 74(5):371-379. PubMed ID: 33106692
[TBL] [Abstract][Full Text] [Related]
12. P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer.
Katayama R; Sakashita T; Yanagitani N; Ninomiya H; Horiike A; Friboulet L; Gainor JF; Motoi N; Dobashi A; Sakata S; Tambo Y; Kitazono S; Sato S; Koike S; John Iafrate A; Mino-Kenudson M; Ishikawa Y; Shaw AT; Engelman JA; Takeuchi K; Nishio M; Fujita N
EBioMedicine; 2016 Jan; 3():54-66. PubMed ID: 26870817
[TBL] [Abstract][Full Text] [Related]
13. Concomitant occurrence of EGFR (epidermal growth factor receptor) and KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutations in an ALK (anaplastic lymphoma kinase)-positive lung adenocarcinoma patient with acquired resistance to crizotinib: a case report.
Rossing HH; Grauslund M; Urbanska EM; Melchior LC; Rask CK; Costa JC; Skov BG; Sørensen JB; Santoni-Rugiu E
BMC Res Notes; 2013 Nov; 6():489. PubMed ID: 24279718
[TBL] [Abstract][Full Text] [Related]
14. Management of Resistance to First-Line Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor Therapy.
Peters S; Zimmermann S
Curr Treat Options Oncol; 2018 May; 19(7):37. PubMed ID: 29808239
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathological features and resistance mechanisms in HIP1-ALK-rearranged lung cancer: A multicenter study.
Kang J; Deng QM; Peng KC; Li P; Zhu BT; Wang P; Chu XP; Zhong WZ; Chen HJ; Wang WX; Chen HF; Rao CZ; Xu CW; Yang JJ
Genes Chromosomes Cancer; 2022 Apr; 61(4):177-186. PubMed ID: 34687488
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic Advances of Rare ALK Fusions in Non-Small Cell Lung Cancer.
Xiang Y; Zhang S; Fang X; Jiang Y; Fang T; Liu J; Lu K
Curr Oncol; 2022 Oct; 29(10):7816-7831. PubMed ID: 36290895
[TBL] [Abstract][Full Text] [Related]
17. Response to ALK-TKIs in a lung adenocarcinoma patient harboring dual DCTN1-ALK and ALK-CLIP4 rearrangements.
Gao F; Gao F; Wu H; Lu J; Xu Y; Zhao Y
Thorac Cancer; 2022 Apr; 13(7):1088-1090. PubMed ID: 35212154
[TBL] [Abstract][Full Text] [Related]
18. A Case of Lung Adenocarcinoma Response to Alectinib Harboring a Rare EML4-ALK Variant, Exon 6 of EML4 Fused to Exon 18 of ALK.
Liu L; Hou F; Liu Y; Li W; Zhang H
J Natl Compr Canc Netw; 2021 Nov; 20(1):2-6. PubMed ID: 34763318
[TBL] [Abstract][Full Text] [Related]
19. Treatment of advanced ALK-rearranged NSCLC following second-generation ALK-TKI failure.
Fukuda A; Yoshida T
Expert Rev Anticancer Ther; 2023; 23(11):1157-1167. PubMed ID: 37772744
[TBL] [Abstract][Full Text] [Related]
20. Deterministic reprogramming and signaling activation following targeted therapy in non-small cell lung cancer driven by mutations or oncogenic fusions.
Rosell R; Pedraz-Valdunciel C; Jain A; Shivamallu C; Aguilar A
Expert Opin Investig Drugs; 2024 Mar; 33(3):171-182. PubMed ID: 38372666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
